WeVote
Log In

Bill

Bill

SB 1285

An Act establishing the Biobonds Innovation Fund, the Biobonds Innovation Fund Loan Program and the Biobonds Innovation Fund Loan Guarantee Program; and providing for duties of Department of Community and Economic Development.

2025-2026 Regular Session Introduced by Frank Farry and 4 co-sponsors

Creates the Biobonds Innovation Fund with loan and loan guarantee programs administered by DCED to finance biotech R&D, facilities, and commercialization in PA.

Referred to Institutional Sustainability & Innovation
0
WeVote Research Nonpartisan
Bill Summary · SB 1285

Summary of Bill: SB 1285 (Session 2025-2026) – Pennsylvania

Overview

SB 1285 proposes the creation of the Biobonds Innovation Fund, along with related loan programs and loan guarantees, to support biotechnology and bioeconomy development in Pennsylvania. The bill designates duties for the Department of Community and Economic Development (DCED) to administer these programs, with the goal of fostering innovation, economic growth, job creation, and advancing regional biotech capabilities.

Primary Purpose and Intent

  • Establish a dedicated funding mechanism—the Biobonds Innovation Fund—to finance biotech-related innovation, research, development, and commercialization.
  • Create three interconnected financing tools:
    1. Biobonds Innovation Fund Loan Program
    2. Biobonds Innovation Fund Loan Guarantee Program
    3. (Implicit) Administrative framework for the Fund and Programs
  • Provide DCED with the authority and duties to implement and oversee these programs, enabling public-private collaboration to attract investment into Pennsylvania’s bioeconomy.

Key Provisions and Mechanisms

  • Biobonds Innovation Fund: Establishes a state-managed fund intended to provide capital for biotech ventures, research facilities, and related infrastructure. The exact capitalization source (e.g., state appropriation, bonding authority, or private matching funds) is described in the bill text.
  • Loan Program: Allows for direct loans to eligible projects, companies, or institutions engaged in biotechnology research, development, manufacturing, or commercialization. Terms likely cover interest rates, repayment schedules, and eligibility criteria, aligned with standard economic development loan practices.
  • Loan Guarantee Program: Allows the Fund to guarantee a portion of private sector loans to qualified biotech projects, reducing lender risk and enabling access to capital for enterprises that may not meet traditional collateral standards.
  • Eligibility and Qualified Activities: Target activities typically include early-stage R&D, pilot production, facility expansion, equipment purchases, and collaborative efforts between research institutions and industry. Preference may be given to projects that demonstrate potential for high-skill job creation, regional economic impact, and alignment with state strategic priorities.
  • Duties of DCED: The Department would administer the Fund and programs, establish criteria, monitor compliance, report on outcomes, and coordinate with other state agencies, economic development organizations, and private partners.
  • Governance and Oversight: Provisions may establish governance structures (e.g., advisory boards, reporting requirements) to ensure accountability, risk management, and alignment with state economic development goals.
  • State and Local Impact: Intended to stimulate biotech industry growth across Pennsylvania, potentially benefiting universities, research hospitals, startups, and manufacturers, with broader regional economic benefits.

Who Would Be Affected

  • Directly Affected:
    • Biotech companies, startups, research institutions, and facilities seeking funding for R&D, scaling, or infrastructure.
    • Financial institutions and lenders participating in the loan guarantee program.
    • University and hospital research programs collaborating with industry.
    • DCED, which would administer and oversee the programs.
  • Indirectly Affected:
    • Local communities and workers through potential job creation in high-skilled biotech sectors.
    • Other state economic development programs through potential funding competition or collaboration.

Procedural and Timeline Aspects

  • Action History: As of the latest entry, SB 1285 was referred to the Committee on Institutional Sustainability & Innovation (April 14, 2026). This indicates initial committee review and potential for amendments before floor consideration.
  • Next Steps: If advanced, the bill would move through committee hearings, potential amendments, and votes in the Senate, then proceed to the House of Representatives for consideration, and ultimately to the governor for signature or veto. Specific timelines would depend on legislative calendars and committee activity.

Notable Considerations

  • The bill’s success hinges on stable capitalization of the Biobonds Innovation Fund, clearly defined loan terms, and robust due diligence and risk management processes.
  • The establishment of a loan guarantee program introduces public-private leveraging, potentially expanding total capital available for biotech projects beyond state appropriations alone.
  • Emphasis on measurable outcomes (jobs, investment, and project milestones) would be important for accountability and ongoing funding.

If you’d like, I can tailor this summary to emphasize specific sections once the full bill text is available, or add a comparison to similar biobond or biotech fund programs in other states.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.